Intranasal rifampicin for Alzheimer's disease prevention

INTRODUCTION: Oral rifampicin has been shown to significantly reduce amyloid β (Aβ) and tau pathologies in mice. However, it shows occasional adverse effects such as liver injury in humans, making its use difficult for a long period. METHODS: To explore safer rifampicin treatment, APP(OSK) mice, a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Umeda, Tomohiro, Tanaka, Akiko, Sakai, Ayumi, Yamamoto, Akira, Sakane, Toshiyasu, Tomiyama, Takami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076366/
https://www.ncbi.nlm.nih.gov/pubmed/30094330
http://dx.doi.org/10.1016/j.trci.2018.06.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076366/
https://www.ncbi.nlm.nih.gov/pubmed/30094330
http://dx.doi.org/10.1016/j.trci.2018.06.012

Ejemplares similares